Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19748545 | 0.87 | CA1 (0.43) | CA1CA2CA9CA12CA4 | |
| SCHEMBL22396640 | 0.77 | ACP1 (0.39) | CA1CA2CA9CA12CA4 | |
| SCHEMBL30876263 | 0.76 | CA1 (0.46) | CA1CA2CA9CA12CA4 | |
| SCHEMBL16177831 | 0.76 | CA1 (0.46) | CA1CA2CA9CA12CA4 | |
| SCHEMBL1541882 | 0.73 | CA1 (0.41) | CA1CA2CA9CA12CA4 | |
| SCHEMBL19747722 | 0.71 | ALDH1A1 (0.38) | CA1CA2CA9CA12 | |
| SCHEMBL31454282 | 0.71 | CA1 (0.48) | CA1CA2CA9CA12CA4 | |
| SCHEMBL16908459 | 0.69 | CA1 (0.35) | CA1CA2CA9 | |
| SCHEMBL20940087 | 0.69 | CA1 (0.40) | CA1CA2CA9CA12CA4 | |
| SCHEMBL121437 | 0.68 | CA2 (0.42) | CA1CA2CA9CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030885-B2 | Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20220251087-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2022-08-11 | — | — | US | disclosed |
| US-10975088-B2 | Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors | INCYTE CORPORATION (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200102315-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2020-04-02 | — | — | US | disclosed |
| US-10479795-B2 | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2019-11-19 | — | — | US | disclosed |
| US-20190119287-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2019-04-25 | — | — | US | disclosed |
| US-10138248-B2 | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2018-11-27 | — | — | US | disclosed |
| US-20180009816-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2018-01-11 | — | — | US | disclosed |
| WO-2017223414-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS | INCYTE CORPORATION (US) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479795-B2 | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CA | CA1 3477/4885CA2 2138/4885CA9 4266/4885 |
| US-12030885-B2 | Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3R5 | CA1 2973/4885CA2 2281/4885CA9 3716/4885 |
| US-20200102315-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | CA1 3294/4885CA2 2677/4885CA9 1533/4885 |
| US-10138248-B2 | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors | PIK3CA, PIK3CG, PIK3CD | CA1 3326/4885CA2 1941/4885CA9 4175/4885 |
| US-10975088-B2 | Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors | PIK3R5, PIK3CD, PIK3CA | CA1 2932/4885CA2 1449/4885CA9 2642/4885 |
| US-20190119287-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | CA1 3294/4885CA2 2677/4885CA9 1533/4885 |
| US-20180009816-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | CA1 3294/4885CA2 2677/4885CA9 1533/4885 |
| US-20220251087-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | CA1 3294/4885CA2 2677/4885CA9 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.